To experimentally confirm whether or not the serum level of CCL5 was affected by changes in bone turnover, we utilized ovariectomized (OVX) female rats as a model of postmenopausal osteoporosis; they were treated with an anti-osteoporotic drug of teriparatide (TPTD), an active fragment of human PTH, of which intermittent administration pharmacologically stimulates bone turnover in a bone anabolic manner (Figure 6b). The gene discussed is CCL5; the disease is postmenopausal osteoporosis.